Clinical Trial Update: TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating darunavir (TMC114) with low-dose ritonavir as monotherapy in antiretroviral-naive HIV patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Darunavir (darunavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 2 | Status: TERMINATED